Biosimilars vs. Interchangeable Biological Products: FDA Fact Check
XTalks
FEBRUARY 8, 2021
As a subset of biosimilars, interchangeable biological products can be substituted for the reference product at the pharmacy level, without the input of the prescribing physician. Significantly, insulin was deemed to be a biologic as of March 23, 2020, making it a reference product for the development of biosimilar versions.
Let's personalize your content